Chan YW, Van den Berg HA, Moore JD, Quenby S, Blanks AM
At LightRx, were not just about losing weight
The osteogenic effect of BPC-157 manifests through multiple mechanisms including stimulation of angiogenesis within bone tissue and enhancement of osteoblast activity
Clinical trials have shown that patients using semaglutide for weight loss experience: Reduced calorie consumption due to decreased hunger Slower gastric emptying, leading to longer-lasting fullness Significant and sustained weight loss over time Improvements in blood pressure, cholesterol, and inflammatory markers In one of the most notable clinical studies, participants who took semaglutide once weekly lost an average of 15% of their body weight over 68 weeks
This represents 1.55% of all 24,484 semaglutide cases filed so far this year